Back to Hematology
Hematologyv2011Evidence-Based

DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis

Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

DIPSS Score: Age >65 (1 point) + WBC >25,000/μL (1 point) + Hemoglobin <10 g/dL (2 points) + Peripheral blast ≥1% (1 point) + Constitutional symptoms (1 point). DIPSS Plus adds: Unfavorable karyotype (1 point) + Platelets <100,000/μL (1 point) + Transfusion dependency (1 point).

Clinical Pearls & Practice Notes

  • DIPSS can be applied at any time during the disease course, unlike IPSS which is only for diagnosis
  • Use DIPSS when karyotype is unavailable; use DIPSS Plus when karyotype is available
  • Constitutional symptoms include fever >37.5°C, night sweats, and weight loss >10% in 6 months
  • Does not incorporate molecular data (JAK2, CALR, MPL mutations)
  • Helps identify high-risk patients who may benefit from allogeneic stem cell transplantation

Evidence & Literature Citations

  1. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8.
  2. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7.

Score Interpretation Ranges

Low risk0 – 0 pts

Low risk category

Intermediate-1 risk1 – 2 pts

Intermediate-1 risk category

Intermediate-2 risk3 – 4 pts

Intermediate-2 risk category

High risk5 – 8 pts

High risk category

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.